Gabriel Yariv - Cannabics Pharmaceuticals COO Pres
| CNBX Stock | USD 0.01 0.00 0.00% |
Insider
Gabriel Yariv is COO Pres of Cannabics Pharmaceuticals
| Age | 47 |
| Phone | 877 424 2429 |
| Web | https://www.cnbxpharma.com |
Cannabics Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (1.0031) % which means that it has lost $1.0031 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (42.8936) %, meaning that it created substantial loss on money invested by shareholders. Cannabics Pharmaceuticals' management efficiency ratios could be used to measure how well Cannabics Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Merav Bassan | Biomx Inc | 58 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| Inbal BenjaminiElran | Biomx Inc | N/A | |
| Yuemei Yan | Ascletis Pharma | 53 | |
| Assaf Oron | Biomx Inc | 50 | |
| Adi ZuloffShani | Clearmind Medicine Common | 55 | |
| John MBA | Ascletis Pharma | N/A | |
| Hejingdao Wu | Ascletis Pharma | 49 | |
| Pr Sorek | Biomx Inc | N/A | |
| Gilad Babchuk | Clearmind Medicine Common | N/A | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| Ming CPA | Ascletis Pharma | N/A | |
| Jinzi Wu | Ascletis Pharma | 60 | |
| Gary Conte | Coeptis Therapeutics | N/A | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| Daniel Yerace | Coeptis Therapeutics | 41 | |
| Kristjan Gudmundsson | Ascletis Pharma | 55 | |
| David Mehalick | Coeptis Therapeutics | 55 | |
| Inbar GahaliSass | Biomx Inc | N/A | |
| George Hill | Ascletis Pharma | 72 | |
| Jonathan MBA | Biomx Inc | 47 | |
Management Performance
| Return On Equity | -42.89 | |||
| Return On Asset | -1.0 |
Cannabics Pharmaceuticals Leadership Team
Elected by the shareholders, the Cannabics Pharmaceuticals' board of directors comprises two types of representatives: Cannabics Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cannabics. The board's role is to monitor Cannabics Pharmaceuticals' management team and ensure that shareholders' interests are well served. Cannabics Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cannabics Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| Gabriel Yariv, COO Pres | ||
| Tal Mofkadi, Financial Board | ||
| Eyal Barad, COO, Director | ||
| Sanja Goldberg, Chief Officer | ||
| Sigalit ArielyPortnoy, Validation Regulation | ||
| Ilya MD, Head Devel | ||
| Yasha Borstein, Chief Data Officer | ||
| Yaakov Waksman, Head Research | ||
| Noam Permont, VP Relations |
Cannabics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Cannabics Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -42.89 | |||
| Return On Asset | -1.0 | |||
| Current Valuation | 6.67 M | |||
| Shares Outstanding | 1.26 M | |||
| Shares Owned By Insiders | 57.59 % | |||
| Price To Earning | 31.09 X | |||
| Price To Book | 20.39 X | |||
| Price To Sales | 7,566 X | |||
| Gross Profit | 7.16 K | |||
| EBITDA | (3.52 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cannabics Pink Sheet Analysis
When running Cannabics Pharmaceuticals' price analysis, check to measure Cannabics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannabics Pharmaceuticals is operating at the current time. Most of Cannabics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cannabics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannabics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cannabics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.